Exploring Atossa Therapeutics, Inc. (ATOS) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Atossa Therapeutics, Inc. (ATOS), and what drives their investment decisions? With a mix of institutional, retail, and insider ownership, the stock presents an interesting case for investors. As of April 2025, retail investors hold a significant portion, around 76.35%, while institutional investors account for approximately 23.17% of the ownership. What does this ownership structure mean for the company's stability and future direction, especially given the recent insider buying activity and a $7.00 analyst price target? Let's delve into the details of who's invested in Atossa, and explore the 'why' behind their investment strategies.

Atossa Therapeutics, Inc. (ATOS) Who Invests in [Company Name] and Why?

Understanding the investor profile of Atossa Therapeutics, Inc. (ATOS) provides valuable insights into the market's perception of the company. A variety of investors are drawn to Atossa Therapeutics, each with their own motivations and strategies.

Key Investor Types:

• Retail Investors: These individual investors often focus on growth stories and recent performance. According to recent data, a significant portion of Atossa Therapeutics' stock is held by retail investors. TipRanks data indicates that approximately 76.35% of Atossa Therapeutics' stock is held by retail investors.
• Institutional Investors: These are organizations that invest on behalf of others, such as pension funds, mutual funds, and insurance companies. They typically invest large sums of money and can significantly influence a company's stock price. Fintel reports that Atossa Therapeutics, Inc. has 172 institutional owners and shareholders, holding a total of 36,266,294 shares. Examples of major institutional investors include:
  • BlackRock, Inc.
  • Vanguard Group Inc
  • Geode Capital Management, Llc
  • State Street Corp
  • UBS Group AG
• Hedge Funds: These are actively managed funds that employ various strategies to generate high returns. Hedge fund ownership in Atossa is part of the institutional ownership.
• Insiders: These are the company's officers and directors. WallStreetZen data shows that 14.77% of Atossa Therapeutics is owned by insiders. Steven C. Quay, the CEO, is the largest individual shareholder.

Investment Motivations:

• Growth Prospects: Investors are often attracted to Atossa Therapeutics due to its potential for growth in the biopharmaceutical industry. The company is focused on developing innovative medicines for breast cancer and other breast conditions.
• Market Position: Atossa Therapeutics operates as a clinical-stage biopharmaceutical company, and is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women's breast cancer.
• Strategic Moves: Atossa's strategic moves, such as its investment in Dynamic Cell Therapies (DCT), can attract investors. In November 2022, Atossa invested $2 million in DCT, acquiring shares equal to 19.99% of its outstanding capital stock, to develop CAR-T therapies.
• Analyst Ratings: Positive analyst ratings can also drive investment. As of April 2025, the average analyst rating for Atossa Therapeutics stock from 3 stock analysts is 'Strong Buy', with an average price target of $7.00.

Investment Strategies:

• Long-Term Holding: Institutional investors often adopt a long-term holding strategy, banking on the company's potential for future growth and success in the biopharmaceutical industry.
• Short-Term Trading: Retail investors may engage in short-term trading, capitalizing on market volatility and fluctuations in the stock price.
• Value Investing: Some investors may view Atossa Therapeutics as undervalued, especially when considering its intrinsic value and future potential. Alpha Spread estimates the intrinsic value of one ATOS stock under the Base Case scenario is $4.683.

Ownership Structure:

The ownership structure of Atossa Therapeutics is a mix of institutional, retail, and individual investors. According to WallStreetZen, Atossa Therapeutics (NASDAQ: ATOS) is owned by:

• 23.17% institutional shareholders
• 14.77% Atossa Therapeutics insiders
• 62.06% retail investors

Key institutional holders include BlackRock, Inc. and Vanguard Group Inc.

Here's a look at the top shareholders as of December 31, 2024:

For further insights into Atossa Therapeutics' financial standing, consider exploring: Breaking Down Atossa Therapeutics, Inc. (ATOS) Financial Health: Key Insights for Investors

Atossa Therapeutics, Inc. (ATOS) Institutional Ownership and Major Shareholders of Atossa Therapeutics, Inc. (ATOS)

Understanding the institutional ownership and major shareholders of Atossa Therapeutics, Inc. (ATOS) provides valuable insights into the company's investor base and market dynamics. Institutional investors, such as mutual funds, hedge funds, and pension funds, often hold significant stakes in publicly traded companies, and their investment decisions can influence stock price and corporate strategy. Examining the composition of Atossa Therapeutics, Inc. (ATOS)'s major shareholders can reveal the level of confidence these institutions have in the company's future prospects.

As of the latest available data from 2024, several institutional investors have significant holdings in Atossa Therapeutics, Inc. (ATOS). These major shareholders include:

• Vanguard Group Inc.
• BlackRock Fund Advisors
• State Street Corp
• Geode Capital Management, LLC
• Citadel Advisors, LLC

These firms represent a mix of investment management companies with diverse investment strategies, ranging from index funds to actively managed portfolios. Their varying investment approaches and risk tolerances can impact their decisions to increase, decrease, or maintain their positions in Atossa Therapeutics, Inc. (ATOS).

Changes in institutional ownership can signal shifts in sentiment and expectations regarding a company's performance. Recent increases in institutional holdings may indicate growing confidence in Atossa Therapeutics, Inc. (ATOS)'s pipeline, clinical trial results, or market opportunities. Conversely, decreases in institutional ownership could reflect concerns about regulatory hurdles, competition, or financial performance. Monitoring these changes over time can provide valuable insights into the evolving perceptions of Atossa Therapeutics, Inc. (ATOS) among institutional investors.

The presence of large institutional investors can have several impacts on Atossa Therapeutics, Inc. (ATOS)'s stock price and corporate strategy. Institutional investors often have substantial resources for research and analysis, allowing them to make informed investment decisions. Their trading activity can influence stock price volatility and liquidity. Additionally, institutional investors may engage with company management to advocate for specific strategies or governance changes. The influence of these large investors can shape Atossa Therapeutics, Inc. (ATOS)'s strategic direction and long-term value creation.

Here is a table summarizing some of the top institutional investors in Atossa Therapeutics, Inc. (ATOS):

These holdings reflect the latest reported figures and may change over time as institutions adjust their portfolios. Understanding the trends in institutional ownership and the motivations behind these investments is crucial for investors seeking to make informed decisions about Atossa Therapeutics, Inc. (ATOS).

For more insights into Atossa Therapeutics, Inc. (ATOS)'s strategic direction, consider reviewing Mission Statement, Vision, & Core Values of Atossa Therapeutics, Inc. (ATOS).

Atossa Therapeutics, Inc. (ATOS) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Atossa Therapeutics, Inc. (ATOS) provides valuable insights into the company's stability, growth potential, and market sentiment. A diverse investor base can offer a buffer against market volatility, while significant institutional ownership may indicate confidence in the company's long-term prospects.

As of April 2025, 23.17% of Atossa Therapeutics, Inc. (ATOS) is owned by institutional shareholders, 14.77% by Atossa Therapeutics insiders, and 62.06% by retail investors.

Here's a breakdown of notable investors and their influence:

• BlackRock, Inc.: As one of the largest asset managers globally, BlackRock's holdings in Atossa signal a significant institutional interest. As of December 31, 2024, BlackRock held 9,759,549 shares. Their investment decisions can influence market perception and stock movement.
• Vanguard Group Inc: Another major institutional investor, Vanguard, also holds a substantial number of shares. As of December 31, 2024, Vanguard held 6,618,969 shares. Vanguard's investment approach, often focused on long-term value, can provide stability to the stock.
• Steven C. Quay: The largest individual shareholder, owning 9.68M shares representing 7.49% of the company, is valued at $5.86M. As Chairman, President, and CEO, Quay's stake aligns his interests with the company's success.
• Shuchih Chen: Another insider, holds 9,095,173 shares.
• Geode Capital Management, Llc: A significant institutional holder with 2,814,177 shares as of December 31, 2024.
• State Street Corp: Another major institutional investor with 1,755,369 shares as of December 31, 2024.
• Renaissance Technologies Llc: Held 1,557,632 shares as of December 31, 2024.
• UBS Group AG: Held 1,124,703 shares as of December 31, 2024.
• Northern Trust Corp: Held 1,025,724 shares as of December 31, 2024.

Recent moves by key investors include:

• BlackRock, Inc. increased their position by 0.951%, holding 9,759,549 shares as of December 31, 2024.
• Vanguard Group Inc. increased their position by 0.313%, holding 6,618,969 shares as of December 31, 2024.
• Geode Capital Management, Llc decreased their position by -0.01%, holding 2,814,177 shares as of December 31, 2024.
• State Street Corp increased their position by 1.336%, holding 1,755,369 shares as of December 31, 2024.
• Renaissance Technologies Llc increased their position by 18.897%, holding 1,557,632 shares as of December 31, 2024.
• UBS Group AG increased their position by 1488.721%, holding 1,124,703 shares as of December 31, 2024.
• Northern Trust Corp increased their position by 7.496%, holding 1,025,724 shares as of December 31, 2024.

These changes in holdings reflect ongoing evaluations of Atossa's potential and market conditions. Institutional investors' actions can drive both short-term price fluctuations and long-term valuation.

Here is a summary of insider trading activity:

On March 26, 2025, H. Lawrence Remmel, a Director, bought 10,000 shares at $0.70, holding 10,257 shares.

For further insights into Atossa Therapeutics, Inc. (ATOS) financial health, consider exploring: Breaking Down Atossa Therapeutics, Inc. (ATOS) Financial Health: Key Insights for Investors

Atossa Therapeutics, Inc. (ATOS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Atossa Therapeutics, Inc. (ATOS) is crucial for gauging the company's stability and future prospects. Analyzing major shareholder activity, recent market behavior, and analyst perspectives provides a comprehensive view of how the financial community perceives Atossa's potential.

Investor sentiment toward Atossa Therapeutics can be assessed by examining the trading activity of its major shareholders. Positive sentiment is typically reflected in increased buying activity, while negative sentiment may manifest as selling pressure. Significant changes in ownership by institutional investors often signal shifts in confidence regarding the company's future performance. Unfortunately, pinpointing the exact current sentiment (positive, neutral, or negative) requires real-time data that fluctuates rapidly. Reviewing recent news releases, SEC filings (such as Form 4 filings for insider trading), and institutional ownership updates can offer insights into prevailing sentiment.

Recent market reactions to Atossa Therapeutics are vital for understanding how the stock responds to changes in ownership or large investor moves. For example, a significant purchase by a well-known institutional investor might lead to a short-term increase in the stock price, reflecting increased confidence in the company. Conversely, a large sell-off could trigger a price decline. Monitoring stock charts and news feeds around the dates of major ownership changes can provide valuable context. Keep an eye on:

• Trading Volume: Spikes in trading volume often accompany significant investor activity.
• Price Movements: Note any sharp increases or decreases in the stock price following announcements of ownership changes.
• Market Sentiment Indicators: Tools like the put-call ratio or volatility indices can provide broader context on market sentiment.

Analyst perspectives play a crucial role in interpreting the impact of key investors on Atossa Therapeutics' future. Analysts often provide insights into why certain investors are taking positions in the company, and how these moves might affect the stock's outlook. Their reports may cover topics such as:

• Rationale for Investment: Understanding why major investors are buying or selling shares.
• Impact on Stock Price: Predictions on how investor activity could influence the stock's valuation.
• Long-Term Prospects: Assessment of the company's future based on current investor positions and strategic moves.

To gain a clearer picture, consider the following hypothetical scenario:

In this scenario, positive reactions to increased institutional investment are tempered by concerns over insider selling, showcasing the dynamic interplay between investor actions, market responses, and expert analysis.

For further insights into Atossa Therapeutics' financial standing, you might find this resource helpful: Breaking Down Atossa Therapeutics, Inc. (ATOS) Financial Health: Key Insights for Investors